Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma Market

Mesothelioma is a rare, aggressive form of malignant tumour caused by inhaled asbestos fibres and forms in the lining of the lungs, abdomen, or heart. Pleural mesothelioma is a cancer of the pleura that is the mesothelium surrounding the lungs.


Malignant Pleural Mesothelioma Epidemiological Segmentation 

The Epidemiological Segmentation of Malignant Pleural Mesothelioma in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incidence of Mesothelioma
  • Total Incident Cases of Malignant Pleural Mesothelioma
  • Total Incident Cases segmented by Age and Gender
  • Total Type-specific Cases 
  • Total Incident Cases by Stages
  • Treated Patient Pool 


Malignant Pleural Mesothelioma Epidemiology 

  • The total incident cases in 7MM in 2017 were 11,431
  • The incident cases in the United Kingdom in 2017 were 2,495
  • The total incident cases in the United States were 2,627 in 2017


Malignant Pleural Mesothelioma Market

The therapeutic market of Malignant Pleural Mesothelioma in 7MM in 2017 was USD 290 million  

  

Malignant Pleural Mesothelioma Market Drivers

  • Rapidly Evolving Landscape of New Therapeutic Opportunities
  • Developments in Diagnosis and Staging
  • Rich Emerging Pipeline


Malignant Pleural Mesothelioma Market Barriers

  • The decline in the Incidence Rate of Malignant Pleural Mesothelioma
  • Failure of Investigational Therapies
  • No Clear Regulatory Precedence of Approved Therapies


Malignant Pleural Mesothelioma Emerging Drugs

The emerging drugs of the Malignant Pleural Mesothelioma market are 

  • TR002
  • Imfinzi
  • Tecentriq Plus Avastin
  • MesoPher
  • Pegargiminase
  • Keytruda
  • Galinpepimut-S (Vaccine)
  • MTG201 Plus Nivolumab
  • Lurbinectedin
  • Yondelis (trabectedin)
  • Nintedanib
  • Avelumab
  • Napabucasin
  • Anetumab Ravtansine (BAY 94-9343)
  • TC-210
  • YS110
  • ONCOS-102
  • iCasp9M28z
  • Alisertib (MLN8237)

And many others. 


Malignant Pleural Mesothelioma Key Players

The key players in the Malignant Pleural Mesothelioma market are

  • Trizell
  • AstraZeneca
  • Hoffmann-La Roche
  • Amphera BV
  • Polaris Pharmaceuticals
  • Merck Sharp & Dohme Corp
  • Sellas Life Sciences Group
  • Momotaro-Gene
  • PharmaMar
  • Boehringer Ingelheim Limited
  • Pfizer 
  • Sumitomo Dainippon Pharma
  • Bayer
  • ImmunoGen
  • MorphoSys
  • TCR2 Therapeutics
  • Kissei Pharmaceutical
  • Targovax
  • Atara Biotherapeutics
  • Bellicum Pharmaceuticals
  • Takeda 

And many others.